REFERENCES
1. Kuwabara, S., et al., Autologous peripheral blood stem cell transplantation for POEMS syndrome. Neurology, 2006. 66 (1): p. 105-107.
2. Ostrow, L.W., et al., Expanding the spectrum of monoclonal light chain deposition disease in muscle. Muscle & Nerve, 2012.45 (5): p. 755-761.
3. Belhomme, N., et al., Rare myopathy associated to MGUS, causing heart failure and responding to chemotherapy. Annals of Hematology, 2017. 96 (4): p. 695-696.
4. Fermand, J.-P., et al., Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood, 2018. 132 (14): p. 1478-1485.
5. Chahin, N., D. Selcen, and A.G. Engel, Sporadic late onset nemaline myopathy. Neurology, 2005. 65 (8): p. 1158-1164.
6. Eymard, B., et al., Late-onset rod myopathy associated with monoclonal gammopathy. Neuromuscular Disorders, 1993. 3 (5-6): p. 557-560.
7. Engel, A.G., Late-onset rod myopathy (a new syndrome?): light and electron microscopic observations in two cases. Mayo Clinic proceedings, 1966. 41 (11): p. 713-41.
8. Engel, W.K. and M.A. Oberc, Abundant Nuclear Rods in Adult-Onset Rod Disease. Journal of Neuropathology & Experimental Neurology, 1975. 34 (2): p. 119-132.
9. Gyure, K.A., R.A. Prayson, and M.L. Estes, Adult-onset nemaline myopathy: a case report and review of the literature. Archives of pathology & laboratory medicine, 1997. 121 (11): p. 1210-3.
10. Maeda, M.H., et al., Sporadic late‐onset nemaline myopathy as a rare cause of slowly progressive muscle weakness with young adult onset. Muscle & Nerve, 2015. 51 (5): p. 772-774.
11. Monforte, M., et al., Sporadic late-onset nemaline myopathy: clinical, pathology and imaging findings in a single center cohort.Journal of Neurology, 2018. 265 (3): p. 542-551.
12. Schnitzler, L.J., et al., Sporadic late-onset nemaline myopathy: clinico-pathological characteristics and review of 76 cases.Orphanet Journal of Rare Diseases, 2017. 12 (1): p. 86.
13. Uruha, A. and O. Benveniste, Sporadic late-onset nemaline myopathy with monoclonal gammopathy of undetermined significance.Current Opinion in Neurology, 2017. 30 (5): p. 457-463.
14. Kotchetkov, R., A. Dyszkiewicz-Korpanty, and V. Kukreti,Chemotherapy with stem cell transplantation is more effective than immunotherapy in sporadic late onset nemaline myopathy with monoclonal gammopathy. Bone Marrow Transplantation, 2018. 53 (7): p. 895-899.
15. Naddaf, E., et al., Sporadic late-onset nemaline myopathy: Clinical spectrum, survival, and treatment outcomes. Neurology, 2019.93 (3): p. e298-e305.
16. Broch, K., et al., A Middle-Aged Man Presenting With Progressive Heart Failure, Myopathy, and Monoclonal Gammopathy of Uncertain Significance. JACC: Case Reports, 2020. 2 (5): p. 785-789.
17. Milone, M., et al., Sporadic late onset nemaline myopathy responsive to IVIg and immunotherapy. Muscle & Nerve, 2010.41 (2): p. 272-276.
18. Keller, C.E., et al., Adult-Onset Nemaline Myopathy and Monoclonal Gammopathy. Archives of Neurology, 2006. 63 (1): p. 132-134.
19. Voermans, N.C., et al., SPORADIC LATE-ONSET NEMALINE MYOPATHY EFFECTIVELY TREATED BY MELPHALAN AND STEM CELL TRANSPLANTSYMBOL.Neurology, 2008. 71 (7): p. 532-534.
20. Doppler, K., et al., Sporadic late onset nemaline myopathy and immunoglobulin deposition disease. Muscle & Nerve, 2013.48 (6): p. 983-988.
21. Dalakas, M.C. and S.A. Smith, A “nema” of hope in the treatment of late-onset nemaline myopathySYMBOL. Neurology, 2008.71 (7): p. 472-473.
22. Matsuzaki, K., et al., Marked improvement by high-dose chemotherapy and autologous stem cell transplantation in a case of light chain deposition disease. Journal of Nephrology, 2011. 24 (2): p. 246-249.
23. Weichman, K., et al., Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplantation, 2006.38 (5): p. 339-343.
24. Merlini, G. and M.J. Stone, Dangerous small B-cell clones.Blood, 2006. 108 (8): p. 2520-30.
25. Jantunen, E., et al., Early treatment‐related mortality in adult autologous stem cell transplant recipients: a nation‐wide survey of 1482 transplanted patients. European Journal of Haematology, 2006.76 (3): p. 245-250.
26. Benveniste, O., et al., STEM CELL TRANSPLANTATION IN A PATIENT WITH LATE-ONSET NEMALINE MYOPATHY AND GAMMOPATHYSYMBOLSYMBOL.Neurology, 2008. 71 (7): p. 531-532.
27. Novy, J., et al., Chemotherapy is successful in sporadic late onset nemaline myopathy (SLONM) with monoclonal gammopathy. Muscle & Nerve, 2010. 41 (2): p. 286-287.
28. Voermans, N.C., et al., Sporadic late-onset nemaline myopathy with MGUS. Neurology, 2014. 83 (23): p. 2133-2139.
29. Wang, M., et al., Monoclonal gammopathy with both nemaline myopathy and amyloid myopathy. Neuromuscular Disorders, 2017.27 (10): p. 942-946.
30. Schneider, R., et al., Clinical Reasoning: A 64-year-old man with progressive paraspinal muscle weakness. Neurology, 2016.86 (1): p. e4-e9.
31. Montagnese, F., et al., Sporadic late‐onset nemaline myopathy in a woman with multiple myeloma successfully treated with lenalidomide/dexamethasone. Muscle & Nerve, 2015. 51 (6): p. 934-935.
32. Kumutpongpanich, T., et al., Sporadic late-onset nemaline myopathy with monoclonal gammopathy of undetermined significance (SLONM-MGUS): An alternative treatment using cyclophosphamide-thalidomide-dexamethasone (CTD) regimen. Neuromuscular Disorders, 2018. 28 (7): p. 610-613.